AACR 2022 | Advances in biomarker-directed therapies for gastric cancer

Michael Cecchini, Yale School of Medicine, New Haven, CT, reflects on the progress made in targeted therapies for gastric cancers (GC), recent advances in biomarker studies, and future directions for GC therapy. The development of immune checkpoint inhibitors has had a great impact in the field, beginning with the accelerated approval of pembrolizumab and now nivolumab in a first-line setting in combination with chemotherapy. There is more work needed to refine currently existing biomarkers such as PL1, CPS and HER2 to identify potential responders to targeted therapy. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.